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Paying for Prescribed Drugs in Medicaid: Current Policy
and Upcoming Changes
Brian Bruen and Katherine Young

Since the early 2000s, state Medicaid programs have made concerted efforts to control the cost of prescription
drug spending. One crucial aspect in doing so is using a pharmacy reimbursement methodology that best
reflects actual drug costs. Currently, states set pharmacy reimbursement policy within broad federal guidelines,
resulting in a complex mix of reimbursement rules. Many states use list prices to set reimbursement levels, and
these list prices increasingly have been criticized as not accurately reflecting the cost of the drug. Specifically,
there are concerns that some benchmarks lead to inflated reimbursement levels. As a result, the federal
government has proposed new rules that aim to make reimbursement policies more closely match the cost of
obtaining and filling prescriptions. However, the change in policy may have varying effects on reimbursement,
depending on the state’s current approach and the type of drug in question. This paper explains current
Medicaid pharmacy reimbursement methodology and examines the potential effect of the proposed rule
changes.

State Medicaid programs reimburse pharmacies for prescription drugs based on the ingredient costs for the
drug and a dispensing fee for filling the prescription. States use a variety of benchmarks to set reimbursement
for the ingredient costs. Concerns about the accuracy of drug pricing benchmarks commonly used, particularly
average wholesale price (AWP) and wholesale acquisition cost (WAC), have led states and the federal
government to look for new ways to determine payment levels. In February 2012, the Centers for Medicare &
Medicaid Services (CMS), released a draft rule that would change the basis of payment for Medicaid-covered
drugs from an “estimated acquisition cost” (EAC) to an “actual acquisition cost” (AAC). CMS proposed this
change, because it feels that AAC will more accurately reflect the actual prices that pharmacies pay to acquire
drugs.1 In addition to modifying the language of drug reimbursement, the draft rule suggested ways that states
could determine AAC; a final rule is anticipated this year.

This paper explains current pharmacy reimbursement
methodology; examines proposed and final rule changes
that CMS has issued; reviews outside studies on drug
pricing benchmarks and how they compare to each other;
and provides independent analysis on how one possible
AAC measure, the National Average Drug Acquisition
Cost (NADAC), compares to previously used EAC
measures.

 EAC: Estimated Acquisition Cost; EAC is a
benchmark used by many state Medicaid
programs to set payment for drug ingredient
costs
 AWP: Stands for “Average Wholesale
Price,” but is more akin to a sticker price;
AWP is one benchmark used to calculate
EAC
 WAC: Wholesale Acquisition Cost; WAC is
one benchmark used to calculate EAC
 AAC: Actual Acquisition Cost
 NADAC: National Average Drug
Acquisition Cost; NADAC can be used to
calculate AAC
 FUL: Federal Upper Limit; FUL sets a
reimbursement limit for some generic drugs
 MAC: Maximum Allowable Cost; MACs are
reimbursement limits set by states in
addition to the FUL
 AMP: Average Manufacturer Price; AMP is
used to calculate drug rebates. The ACA also
established that it would replace list prices
as the basis for FULs, but this has not yet
been implemented



While CMS has proposed to move from EAC to
AAC, EAC is still currently used as the basis of
payment for Medicaid-covered drugs in most
states. Most states calculate EAC by applying a
percentage reduction to Average Wholesale Price
(AWP) or a percentage increase to Wholesale
Acquisition Cost (WAC). In September 2013, 12
states used AWP as their primary reimbursement
metric, 16 states used WAC, and only 6 states used
AAC. 17 states used a combination of benchmarks
in setting reimbursement levels.



To better understand the prices that pharmacies
pay to acquire drugs, the US government and outside groups have conducted numerous studies
comparing drug pricing benchmarks to each other, as well as measures of acquisition costs. These
studies have shown that the relationships among list prices (WACs and AWPs) and average prices paid
(Average Manufacturer Prices, or AMPs) depends on whether a drug is a single-source brand, multiplesource brand, or generic. They have also shown that AMPs were consistently less than AWPs and
generic WACs, but much closer to brand WACs.



Independent analysis in this brief finds that one proposed AAC measure, the NADAC, is below
currently-used benchmarks for single-source drugs. For single-source drugs, NADACs are well below
AWPs and just slightly less than WACs. We found that the difference between generic NADACs and
generic benchmarks became more exaggerated. We also found that actual Medicaid payments to retail
pharmacies for prescribed drugs are much closer to WAC and NADAC prices than to AWP.



Any reimbursement formula that uses fixed percentages, such as AWP minus 16 percent or WAC plus 4
percent, results in pharmacy profits that vary based on the price of the drug.



Dispensing fees are an important factor in overall pharmacy reimbursement. Today, dispensing fees
range from $2 to $10, with an average of $5 or less per prescription. Changes in ingredient costs could
have implications for dispensing fees; as states switch to using AACs for drug reimbursement,
dispensing fees are likely to rise.



Although reimbursement policy is important, there are other factors that also affect Medicaid spending
on prescription drugs, such as the demand for extremely expensive specialty drugs.
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At nearly $16 billion in FY 2010, prescription drug spending is a significant component of Medicaid total
spending.2 Although in recent years, Medicaid prescription drug spending has been growing more slowly than
in the early 2000s, it remains an area of concern. Medicaid prescription drug spending is driven by many
factors, including utilization and reimbursement. Medicaid programs reimburse pharmacies for outpatient
drugs based upon a drug ingredient cost and a dispensing fee. Revising drug ingredient cost reimbursement
methodology continues to be an area for potential cost savings. In 2011, U.S. Department of Health and Human
Services Secretary Kathleen Sebelius wrote to the state governments to inform them that the federal
government would help states identify cost drivers and provide states with new ways to achieve cost savings.
More effective drug ingredient costs were one of many items relating to pharmaceutical services in a long list.3
Reimbursement methodology is just one factor that determines how much states and the federal government
spend on Medicaid outpatient prescription drugs. Rebates at the federal and state levels offset some of this
spending; in FY 2010, rebates accounted for over 40 percent of the $27 billion in pre-rebate Medicaid drug
spending.4 Since 1991, federal law has required manufacturers wishing to have their products covered by any
Medicaid program to participate in the Federal Medicaid Drug Rebate Program. In 2010, Congress raised the
minimum required rebate level as part of the Affordable Care Act, and expanded the rebate requirement to
include drugs paid for by Medicaid managed care plans.5
When managed care plans cover drugs as part of the package of services for which they receive capitated
payments from the state Medicaid agency, the plans establish the reimbursement levels paid to pharmacies.
Prior to passage of the Affordable Care Act, several states with comprehensive Medicaid managed care plans
carved out their prescription drug benefits—i.e., paid for drugs on a fee-for-service basis rather than including
them in the package of services for which plans received capitated payments—in order to collect manufacturers’
rebates, because these discounts were not required when managed care plans paid for the prescription. The
Affordable Care Act required manufacturers to provide rebates on all Medicaid-covered drugs purchased by
managed care plans for their Medicaid clients, effective March 23, 2010. Proponents of incorporating drug
benefits into the package of managed care services tend to highlight potential advantages from better
coordination of pharmacy services with other medical care and administrative tasks handled by managed care
plans. Arguments for carving out drugs generally focus on potential differences in formularies, prior
authorization, benefit management processes among health plans, and concerns that plans may not have the
same incentives to maximize federal or state rebates. 6 Although this paper primarily focuses drug
reimbursement, it is important to keep in mind that there are other policies that affect Medicaid drug
spending.
In this paper, we examine current Medicaid pharmaceutical reimbursement policy and explain how and why
the policy is changing. We then consider research on how Medicaid drug pricing metrics compare. Finally, we
conduct our own analysis on how the recently created NADAC compares to other pricing metrics.

Medicaid payments to retail pharmacies for prescription drugs are determined by a complex set of policies
developed at both the federal and state levels. Reimbursement is a factor of ingredient cost, dispensing fees,
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and any cost sharing paid by the beneficiary. States set policies on dispensing fees and, within federal
guidelines, beneficiary cost-sharing. With respect to ingredient costs, with the exception of some multiplesource drugs7 for which there are specific federal or state limits, federal regulations require Medicaid programs
to reimburse pharmacies based on the lesser of the (1) estimated acquisition cost (EAC) plus a reasonable
dispensing fee; or (2) the pharmacy’s “usual and customary charge” to the public. 8

EAC is intended to reflect the price that providers and retail pharmacies generally and currently pay to procure
a particular drug from its supplier. Most states determine EAC using formulas that apply either a percentage
reduction from the average wholesale price (AWP) for the drug or a percentage increase to the wholesale
acquisition cost (WAC) for the drug. (See Figure 1).
AWPs and WACs are prices published in commercially available drug pricing compendia. Although its name
suggests that it is the actual price that wholesalers charge for a drug, critics and experts alike have noted that
AWP is more akin to the sticker price on a car: it represents a starting point for negotiations. It does not
include any discounts or rebates that would typically be incorporated in the actual price that the wholesaler
charges. It is not defined in federal regulations. Similarly, WAC is not based on actual sales data. However,
unlike AWP, WAC is defined in federal regulations.9
Figure 1

Numbers of State Medicaid Programs Using AWP, WAC, AAC, or
Multiple Measures as their Primary1 Drug Reimbursement
Benchmarks, Quarter Ending September 2013
17
16

12

6

Average Wholesale Price
(AWP)

Wholesale Acquisition
Cost (WAC)

Actual Acquisition
Cost (AAC)2

Multiple Measures3

SOURCE: CMS, “Medicaid Prescription Reimbursement Information by State – Quarter Ending September 2013”.
NOTES: 1. Numbers reflect the primary benchmark used. For example, if a state uses AWP minus a percentage, but will substitute
WAC plus a percentage when there is no AWP, then it is listed as an AWP state.
2. All states currently using AAC use WAC as the alternative when AAC is not available.
3. States using multiple benchmarks typically have “lesser of” formulae that may include both AWP minus a percentage and WAC
plus a percentage.

Multiple-source drugs are drugs that are available from more than one manufacturer. The Federal Upper
Limit (FUL) program caps reimbursement for certain multiple-source drugs, with the intent of making the
government a prudent buyer – and reducing Medicaid expenditures – by basing payments on market prices for
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these drugs. CMS calculates a FUL amount for specific forms and strengths for each multiple-source drug that
meets the established criteria. The federal government establishes maximum payment amounts for about 700
multiple-source drugs, which include both generics and originator brands for which generic versions are
available. According to CMS, FUL drugs accounted for $2.4 billion in Medicaid expenditures in 2010,10 9% of
Medicaid spending on prescription drugs. 11
Traditionally, the FUL for a multiple-source drug was set at 150% of the lowest price published in national drug
pricing compendia. The Deficit Reduction Act (DRA) of 2005 included provisions to substantially reduce FULs,
based in part on findings from a federal study that indicated that FULs based on published prices (AWP or
WAC) were significantly higher than pharmacies’ acquisition costs.12 CMS did not implement these rules
because of an injunction and subsequent changes to federal law. The Affordable Care Act and subsequent
proposed rules limit reimbursement to no less than 175% of the weighted average of the most recently reported
average manufacturer prices (AMP) for that drug. Federal law defines AMP as the average price paid to
the manufacturer for the drug in the United States by (1) wholesalers for drugs distributed to retail community
pharmacies and by (2) retail community pharmacies that purchase drugs directly from the manufacturer.13
CMS began publishing draft FULs based on these rules in September 2011 and continues to release updates for
review and comment,14 but as of the date of this publication, FUL amounts continue to be based on published
prices.

Nearly all states apply maximum allowable cost (state MAC, or SMAC) limits to multiple-source drugs,
which establish ceilings on reimbursement for the drug products included on state MAC lists. These state MAC
amounts generally are part of a complex “lesser of” formula, where the state agency sets reimbursement for
multiple-source drugs at the lowest amount for each drug based on (1) the state’s EAC formula, (2) the FUL (if
applicable), (3) the state MAC or (4) the pharmacy’s usual and customary charge to the public. State MAC
programs frequently include other drugs that do not have established FULs: a 2013 analysis by the U.S.
Department of Health and Human Services’ Office of Inspector General (OIG) found that state MAC programs
include 50-60 percent more drugs than FULs. Of 41 states that identified a pricing benchmark for their state
MAC programs, 29 used pharmacy acquisition costs as part of the benchmark to set state MAC prices.15

The dispensing fee is intended to cover reasonable costs associated with providing the drug to a Medicaid
beneficiary, including the pharmacist’s services and overhead associated with maintaining the facility and
equipment necessary to operate the pharmacy. States establish dispensing fees for the pharmacies that fill
prescriptions for Medicaid beneficiaries. In late 2013, these fees range from $2 or less per prescription in
Arizona, Connecticut, New Hampshire, Ohio, and Pennsylvania to more than $10 in Alabama, Alaska,
Colorado, Idaho, Iowa, Louisiana, and Oregon; most other states pay dispensing fees that average around $5 or
less per prescription.16 In setting their fees, states look to the fees paid by other state Medicaid programs, as
well as fees paid in private insurance programs and Medicare Part D plans. Although exact pricing for most
plans is proprietary information, surveys from groups such as the Pharmacy Benefit Management Institute and
the Kaiser Family Foundation, and drug benefit trend reports from pharmacy benefit managers (PBMs) such as
CVS/Caremark and Express Scripts, offer insight into typical benefit designs including general pricing trends
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and dispensing fees.17,18,19,20 Variation in fees also reflect differences in states’ approaches to EAC: except for
Alaska, the states with the highest fees also use AAC-based reimbursement.
Pharmacies often argue that dispensing fees do not adequately cover their “cost of dispensing”. Estimates from
a study supported by retail pharmacies indicate that retail pharmacies’ average cost of dispensing nationwide
was $10.50 per prescription (each pharmacy’s average cost weighted by prescription volume) or $12.10 per
pharmacy (each pharmacy’s average cost counted once) in 2006.21 State-specific averages per pharmacy ranged
from $10.36 to $15.91 in that study. Subsequent state-funded studies estimated an average cost of dispensing
of $12.97 per pharmacy in Alabama in 200922 and an unweighted average cost of dispensing of $11.15 per
pharmacy in Oregon that same year.23 These states use AAC-based reimbursement with dispensing fees of
$10.64 (Alabama) and $9.68 to $14.01, varying by volume (Oregon).24 Alabama pays additional fees to
pharmacists for special services such as pill-splitting or long-term drug maintenance.25

A final component of Medicaid reimbursement for prescription drugs is cost sharing paid by the beneficiary.
Medicaid has traditionally imposed limits on cost sharing. Until the enactment of the Deficit Reduction Act
(DRA) of 2005, prescription drug copayments were limited to “nominal” levels, usually $3 per prescription
except under Medicaid waiver, although some groups of enrollees, including children and pregnant women,
could not be charged. In addition, under Medicaid policy, even if copayments were imposed and beneficiaries
could not pay, pharmacies were supposed to dispense the drug anyway. The DRA modified these policies,
allowing states to increase nominal cost-sharing levels based on the Consumer Price Index for Medical Care
and permitting higher cost-sharing levels for beneficiaries with incomes over 100 percent of poverty as well as
alternative cost-sharing policies. Today, almost all state Medicaid programs and Medicaid managed care plans
charge nominal copayments for prescription drugs for adults, although they sometimes have variations in the
copayment level based on whether a medication is generic or branded, or whether it is designated a “preferred”
drug in the state’s Medicaid program.
Final rules issued by CMS in July 2013 allow states to require cost-sharing of up to $4 for preferred drugs and
$8 for non-preferred drugs for all Medicaid-covered individuals, including individuals with incomes at or
below 150% of the federal poverty level (FPL). For individuals with incomes above 150% of the FPL, the new
rules allow states to establish higher cost sharing, including coinsurance of up to 20% of the cost of the drug,
for non-preferred drugs.26,27
In making decisions about imposing cost-sharing, states will need to weigh a large body of evidence about the
effects of beneficiary cost sharing. A systematic review of cost sharing literature by Goldman et al. found that
increases in cost sharing are associated with decreased use, poorer adherence, and more frequent
discontinuation of prescription medicines.28 The literature also suggests that when higher cost sharing for
prescription medications leads to reduced utilization and adherence, it can engender increases in other medical
costs if patients become sicker as a result.29,30,31, 32,33
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In the early 1990s, the Health Care Financing Administration34 pressured states to improve their estimates of
acquisition costs based on evidence that AWP was higher than pharmacies’ actual costs of acquiring drugs from
a wholesaler or manufacturer.35 Over the next two decades, federal investigations continued to show that AWPbased payments exceeded pharmacies’ acquisition costs, despite states’ efforts to bring reimbursement in line
with costs.36,37,38,39 Regardless, until recently, the majority of states used AWP to determine reimbursement
amounts; for example, at the end of 2010, 34 states still based their EAC on AWP.40
In 2009, First DataBank and Medi-Span, publishers of the most widely used drug price compendia, settled
lawsuits that alleged they had inflated AWPs to benefit pharmacies and wholesalers with higher payments, at
the expense of purchasers (including state and federal governments). These lawsuits supported claims that
AWP does not reflect actual transaction cost and confirmed suspicions that it may be subject to manipulation.
In 2009, First DataBank announced they would cease publishing AWPs within two years. Medi-Span made a
similar announcement at that time, but later reversed the decision, and as a result, they continue to publish
AWPs today. However, the announcements that widely used sources would no longer list AWP, combined with
the attention to the subject resulting from and abundance of studies and litigation on the topic caused many
states and industry groups to discuss alternatives to the AWP. WAC seems to suffer much criticism because of
its close relationship to AWP. However, there is evidence that WAC is actually a relatively accurate pricing
measure for many single-source drugs (brand-name medications with market exclusivity) but it is less
accurate, if even reported, for many multiple-source drugs (generic versions of brand-name drugs).41

In this atmosphere, and in direct response to the OIG’s extensive research on the actual acquisition cost and
AWP, in February 2012, CMS issued proposed rules that would require states to pay pharmacies based on
actual acquisition cost (AAC) plus a “professional” dispensing fee, instead of the current EAC plus a
reasonable dispensing fee.42 In the proposed rule, CMS defines AAC as the state Medicaid agency’s
determination of pharmacy providers’ actual prices paid to acquire drug products marketed or sold by a
specific manufacturer. To determine AAC, CMS suggests in the proposed rule that states may survey
pharmacies, as is currently done by every state using AAC-based reimbursement, or use the AMP data that
manufacturers already are required to report to enable calculations of federal rebates and FUL pricing. The
Office of Management and Budget has indicated the final rule is scheduled to come out in mid-2014.43
A 2011 survey by the Department of Health and Human Services’ Office of the Inspector General (OIG) found
that most states want CMS to create a national benchmark for Medicaid reimbursement of prescription drugs. 44
The proposed rule from February 2012 also mentioned that a national survey could be used to develop an AAC
metric. To this end, CMS contracts with a public accounting firm to perform a survey of invoices from
independent and chain retail pharmacies, which it uses to calculate National Average Drug Acquisition
Costs (NADAC) values.45 CMS began to post draft NADAC data to a public website in October 2012. Effective
November 27, 2013, CMS is posting final NADAC data, updated on a weekly and monthly basis.46 CMS views
these data as a way of providing Medicaid agencies with information concerning acquisition costs, which state
Paying for Prescribed Drugs in Medicaid: Current Policy and Upcoming Changes

7

agencies can use to compare pricing methodologies and payments. If a state agency chooses to use NADAC as
its metric to determine reimbursement, it would have to submit a state plan amendment to CMS for approval.
Commercial entities have also developed alternative measures to estimate actual acquisition costs. For
example, Elsevier/Gold Standard, a drug database and drug reference provider, promotes use of a new pricing
metric it calls Predictive Acquisition Cost (PAC). This metric comes from a predictive analytic model that
estimates drug acquisition cost based on factors such as industry maximum allowable cost benchmarks,
published prices, existing price benchmarks, drug dispensation metrics, supply-demand measures, and surveybased acquisition costs.47

The U.S. Department of Health and Human Services’ Office of Inspector General (OIG) and the U.S.
Government Accountability Office (GAO) have issued several studies that indicate how drug pricing
benchmarks relate to each other and to measures of acquisition costs, FULs, and state MACs. These studies
emphasize that relationships between list prices (AWPs and WACs) and average prices (AMPs) differ based on
whether a drug is a single-source brand, multiple-source brand, or generic. They show AMPs were consistently
less than AWPs and generic WACs, but AMPs were relatively close to brand WACs. They also show AMPs were
close to single-source brand invoice prices, but the relationship was much more variable for multiple-source
brands and generics without FULs. Additionally, they showed that AMP values vary considerably from month
to month. See Appendix Table 1 for a more complete review of OIG, GAO, and other existing research on the
comparison of drug pricing metrics.

Because the NADAC is a new measure, there is little current research on its relationship to other pricing
metrics. Our goal was to understand how the NADAC, an AAC measure, compares with the EAC measures and
ultimately how they compare with the current amounts that Medicaid pays. To do this, we compared AWPs,
WACs, NADACs, and amounts paid for different drugs. We merged several sources of data at the National
Drug Code (NDC)48 level. We grouped the NDCs by brand, generic, therapeutic class, and therapeutic
subclass. Finally, we calculated the weighted averages of AWPs, WACs, NADACs, and amounts paid for the top
25 brand, top 25 generic, top 100 generic, and therapeutic class. The calculation of current payment levels
takes into account each state’s EAC computations and the effects of FULs, state MACs and usual and customary
charges. Further details on our methodology are provided in the Methods section at the end of this report.

Figure 2 shows that among the top 25 single source brands and top 25 multiple source brands, the average
NADAC ($8.03) is about 18 percent less than the average AWP ($9.78), but just slightly less than the average
WAC ($8.14). Average WACs and NADACs for brand drugs are less than the amount that Medicaid pays
($8.33). However, it is important to note that the actual paid amounts include dispensing fees, and are
reduced by patient cost sharing and amounts paid by third parties, which are not accounted for in the AWP,
WAC, or NADAC. To get a sense for this, if we assume that the average prescription for the top 25 single source
brand drugs used to compute the values shown in Figure 2 contains 35 units (based on calculations using our
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source data), that the average dispensing fee is $5 per prescription ($0.14 per unit), and that there are
negligible amounts of third party payment and cost sharing (reasonable assumptions at the national level),
then the weighted average total amount paid per unit absent these amounts would be about $8.19. We then
approximate that for the top 25 single-source brand drugs, NADACs are just slightly less than actual Medicaid
payments for the drug ingredient cost.
Figure 2

Pricing Metric Per Unit Comparison for Top 25 Brands by
Number of Prescriptions
$9.78
$8.14

$8.03

$8.33

$7.96

$6.62

Weighted
Avg Unit
AWP

Weighted
Avg Unit
WAC

Weighted Wgt Avg Ttl
Avg Unit Amt Paid Per
NADAC
Unit

Top 25 Single Source Brands

Weighted
Avg Unit
AWP

Weighted
Avg Unit
WAC

$6.50

$6.88

Weighted Wgt Avg Ttl
Avg Unit Amt Paid Per
NADAC
Unit

Top 25 Multiple Source Brands

SOURCE: CMS Drug Utilization Data, 2011Q4-2012Q3; Wolters Kluwer Master Drug Data Database, Version 2.5, March 1, 2013;
CMS NADACs, October 4, 2012.

Table 1 shows the prescription-weighted, per-unit average AWP, WAC, NADAC and total amount paid for
single source brand drugs grouped into therapeutic drug classes. Across therapeutic classes, NADAC is usually
very close to WAC— 1 % to 2% higher or lower— although there are larger differences in a few classes. Table 1
also reaffirms that the acquisition costs are well below AWPs.
The analysis by therapeutic drug class also highlights the significant challenges in developing reimbursement
formulas caused by great variation in drug prices. Any formula using a fixed percentage increase or decrease
from a benchmark, such as AWP minus 16% or WAC plus 4%, results in markups (or markdowns) that vary in
actual dollar amounts based on the price of the drug. The data in Table 1 illustrate this result: for example, the
difference between the weighted average actual amount paid and the weighted average NADAC, per unit, is
$0.20 for drugs the Cardiovascular Drugs class but $1.40 for the generally more expensive Anti-infective
Agents class.
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Central Nervous System Agents

$10.36

$8.63

$8.52

$8.80

4,840,803

Hormones and Synthetic Substitutes

$4.85

$4.03

$3.95

$4.20

927,027

Cardiovascular Drugs

$4.57

$3.80

$3.75

$3.95

924,381

Anti-infective Agents

$30.68

$25.56

$25.00

$26.40

822,343

Gastrointestinal Drugs

$5.86

$4.84

$4.75

$4.93

818,167

Vitamins

$1.01

$0.74

$0.68

$0.77

452,696

Autonomic Drugs

$8.26

$6.89

$6.76

$7.17

344,827

$19.66

$16.37

$16.02

$16.44

123,565

Smooth Muscle Relaxants

$6.84

$5.70

$5.60

$5.80

115,256

Blood Formation, Coagulation & Thrombosis

$5.00

$4.16

$4.22

$4.31

62,356

Electrolytic, Caloric, and Water Balance

$2.85

$2.28

$2.22

$2.37

47,612

$100.18

$83.44

$81.24

$82.38

17,855

Respiratory Tract Agents

$4.55

$3.78

$3.72

$3.87

17,617

Antihistamine Drugs

$2.09

$1.70

$1.72

$1.93

15,957

$24.90

$19.94

$19.41

$21.49

4,715

$0.56

$0.45

$0.42

$0.43

1,224

Miscellaneous Therapeutic Agents

Antineoplastic Agents

Skin and Mucous Membrane Preparations
Eye, Ear, Nose & Throat Preparations

Source: CMS Drug Utilization Data, 2011Q4-2012Q3; Wolters Kluwer Master Drug Database, Version 2.5, March 1, 2013; CMS NADACs,
October 4, 2012.

For generic drugs, the differences between the benchmarks and actual amounts paid become more
exaggerated. Although there are AWPs for generic drugs, the values are high and generally not reflective of
actual transaction prices. Due to substantial discounts from AWP, aggressive state MAC rates established by
states to pay for generic drugs, and usual and customary amounts, generics are more likely to be reimbursed at
rates far below AWP values. As with brand-name drugs, WAC values tend to be much closer to actual paid
amounts and relatively close to NADAC values.
Because generic drugs have much lower per-unit prices, the dispensing fee is a more important factor in the
difference between paid amounts and benchmarks. The average prescription for the top 25 generic drugs used
to compute the values shown in Figure 3 contains 46 units. If one assumes an average dispensing fee of $5 per
prescription ($0.11 per unit) and negligible amounts of third party payment and cost sharing, which again are
reasonable assumptions at a national level, the weighted average total amount paid per unit absent these
amounts would be about $0.24 per unit, which falls between the weighted average WAC ($0.39) and NADAC
amounts ($0.14).
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As with brand-name drugs, generic drug prices differ considerably. Table 2 illustrates the variation in average
benchmarks and actual amounts paid for generic drugs, across drug classes. The lowest prices tend to be in
classes with multiple older, established products that compete with each other for market share, while the
higher prices tend to be in classes with greater concentrations of newer products or fewer competing therapies.
Unlike with the brand drugs, NADACs vary in their relation to WACs by therapeutic class, ranging from 11%
less than WAC for the eye, ear, nose, and throat preparations class to 73% less than WAC for the
gastrointestinal drugs class.
Figure 3

Pricing Metric Per Unit Comparison for Top 25 and Top 100
Generics by Number of Prescriptions
$2.56

$1.88

$0.39

$0.42

$0.35

$0.17

$0.14
Weighted
Avg Unit
AWP

Weighted
Avg Unit
WAC

Weighted Wgt Avg Ttl
Avg Unit Amt Paid Per
NADAC
Unit

Top 25 Generics

$0.47

Weighted
Avg Unit
AWP

Weighted
Avg Unit
WAC

Weighted Wgt Avg Ttl
Avg Unit Amt Paid Per
NADAC
Unit

Top 100 Generics

SOURCE: CMS Drug Utilization Data, 2011Q4-2012Q3; Wolters Kluwer Master Drug Data Database, Version 2.5, March 1, 2013;
CMS NADACs, October 4, 2012.
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Central Nervous System Agents

$2.33

$0.51

$0.27

$0.53

29,748,635

Cardiovascular Drugs

$1.95

$0.32

$0.13

$0.35

11,240,268

Anti-infective Agents

$4.50

$1.28

$0.49

$1.26

6,764,413

Hormones and Synthetic Substitutes

$1.11

$0.62

$0.45

$0.70

6,185,648

Gastrointestinal Drugs

$5.31

$0.60

$0.16

$0.47

5,069,551

Antihistamine Drugs

$0.98

$0.24

$0.13

$0.28

2,948,786

Electrolytic, Caloric, and Water Balance

$0.37

$0.23

$0.14

$0.26

2,102,647

Autonomic Drugs

$1.47

$0.23

$0.10

$0.27

2,096,000

Vitamins

$0.80

$0.55

$0.17

$0.69

1,593,165

Blood Formation, Coagulation & Thrombosis

$2.36

$0.22

$0.08

$0.47

1,067,081

$11.24

$2.55

$1.57

$2.70

531,679

Antineoplastic Agents

$6.49

$1.22

$0.47

$1.24

185,885

Smooth Muscle Relaxants

$1.76

$1.26

$0.54

$0.97

141,244

Skin and Mucous Membrane Preparations

$2.70

$1.28

$0.64

$1.16

127,572

Respiratory Tract Agents

$1.35

$0.51

$0.25

$0.45

69,503

Eye, Ear, Nose & Throat Preparations

$1.94

$1.45

$1.29

$1.29

19,261

Miscellaneous Therapeutic Agents

Source: CMS Drug Utilization Data, 2011Q4-2012Q3; Wolters Kluwer Master Drug Database, Version 2.5, March 1, 2013; CMS NADACs,
October 4, 2012.

The federal government is making efforts to provide more transparent Medicaid drug pricing data, with Health
and Human Services proposing to “increase access to and transparency of Medicaid drug pricing data” in its
2015 budget.49 HHS specifically proposes funding a nationwide survey of pharmacy drug prices to consumers,
and collecting wholesale acquisition costs for all Medicaid-covered drugs. These proposals come amongst many
to reform Medicaid outpatient drug reimbursement in the 2015 HHS budget.

State Medicaid programs use a variety of benchmarks to determine their reimbursements to pharmacies for
prescribed drugs. Due to concerns about the accuracy and availability of commercially available benchmarks
such as AWP, many states have changed the methods they use to determine reimbursement in recent years and
more continue to explore new options. As of December 2013, Alabama, Colorado, Idaho, Iowa, Louisiana, and
Oregon all use surveys of pharmacy invoices in an effort to bring more transparency to drug acquisition costs,
as does CMS’s NADAC measure. Five of these states use the same firm, Myers and Stauffer, LC, to conduct the
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state-wide pharmacy surveys as the federal government does. Alabama was the leader in implementing these
survey-based AACs, having used the AAC model since September 2010. Oregon implemented the model in
January 2011.50
The state AAC and NADAC survey approaches rely on invoices to evaluate the costs that retail pharmacies pay
to acquire prescription drugs from manufacturers or wholesalers; these costs do not account for rebates or
discounts if they are not included on the invoice. Other states have switched from AWP-based formulas to
WAC-based formulas, in part due to studies indicating WAC has a reasonably consistent relationship to invoice
prices. State MACs typically determine reimbursements for the most common multiple-source brand-name
drugs and generics.

The OIG’s analyses indicate that AWP, WAC, and AMP all have relatively consistent relationships with invoice
prices for brands (including single- and multiple-source brands), but larger and more variable relationships
with invoice prices for generic drugs. Our own analysis indicates that actual Medicaid payment amounts to
retail pharmacies for prescribed drugs are much closer to WAC and NADAC prices than to AWP, primarily
because of complex “lesser of” payment formulae and large percentage reductions from AWP used in EAC
calculations. Differences between WAC or NADAC and the actual paid amounts are relatively modest because
states have refined their reimbursement schemes over the past several years in response to concerns about
excessive payment rates and as a way of controlling cost growth. For generic drugs, differences remain
relatively large in percentage terms but are generally modest in terms of actual dollar amounts. Benchmarks
and paid amounts vary considerably by drug class, in part due to the mix of brand name and generic
medications in each class. It is important to note, however, that our analysis only looks at one point in time.
Further, we were examining NADACs from the first month they were issued. It would be worthwhile to
continue looking at these trends using NADACs from other time periods, as well as studying the volatility of
NADACs over time.

Regardless of whether one believes that any benchmark accurately captures final transaction prices at which
retail pharmacies purchase the drugs that they dispense to Medicaid beneficiaries, the right benchmark for
acquisition costs still does not resolve the issue of what constitutes “appropriate” reimbursement under
Medicaid. Retail pharmacies incur costs to build and maintain infrastructure that is convenient for patients
and to employ the staff and technology necessary to safely and accurately dispense medications to patients. To
stay in business, the total compensation they receive, including reimbursement for the cost of the drug and the
dispensing fee, needs to be sufficient to support ongoing operations profitability. Many states have increased
their dispensing fees as they have ratcheted down the acquisition cost component of reimbursement. In a 2011
Kaiser Family Foundation study of Medicaid pharmacy directors, some stated they would spend more money if
they were to base their reimbursements on Alabama AACs, due to the accompanying increased dispensing
fee.51 It should be noted that the pharmacy directors made these comments with regard to Alabama AACs, not
NADACs. The potential savings from using NADACs or any other AAC measure are dependent on the current
and future dispensing fees in each state and the state’s mix of brand and generic prescriptions. Policy-makers
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should not assume that the prescription trends of the past will remain the same in the future. Further, CMS
and numerous experts have expressed the value of basing reimbursement on actual pricing data.52

Concerns over drug costs are increasingly falling outside the purview of traditional pharmacy reimbursement
amounts and related benchmarks. Many new drugs and biologics are “specialty” medications, which may be
dispensed through specialty pharmacies because of unusual distribution or handling requirements. These
products may also require consultation with or monitoring of patients prior to or after administration of the
medication, entailing administration by physicians or other health care providers, and coverage through
medical benefits. Provider involvement adds a layer of complexity because of the necessary coordination of
benefits, payments and rebate collections. Specialty products also tend to be much more expensive than
traditional drugs, so accurate reimbursement is important, regardless of whether the state pays for them
through pharmacies or through medical providers or health care facilities. With their high costs and rapid
growth of utilization, managing specialty drugs will be crucial to limiting state and federal Medicaid
expenditures for prescribed drugs in the near future.
This brief was prepared by Brian Bruen from George Washington
University and Katherine Young from the Kaiser Family Foundation.
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To compare actual drug payments to AWPs, WACs, and NADACs, we combined at the National Drug Code
(NDC) level the CMS drug utilization data, the CMS list of NADACs for October 4, 2012, and the March 1, 2013
version of Wolters Kluwer Master Drug Database (MDDB) Version 2.5. We set the state drug utilization data to
the most recent quarter available. At the time of this analysis, 2012 quarter three drug utilization was available
for 40 states and the District of Columbia, 2012 quarter two for six states, 2012 quarter one for one state, and
2011 quarter 4 for two states. We restricted the sample of interest to all NDCs with NADACs, AWPs, WACs,
and utilization data. NADACs reported on October 2012 are reflective of data from at least a few weeks earlier.
In this analysis we compared the NADACs to AWPs and WACs as of August 1, 2012.
NADAC data are available for drug products grouped by active ingredient(s), strength, dosage form, and route
of administration. Drugs are further classified according to drug category as single-source, innovator multiplesource, or non-innovator multiple-source. Many people refer to drugs in the first two categories using the
colloquial terms “brand-name” or “branded” drugs, and drugs in the latter category as “generic” drugs. Using
the MDDB, we similarly classified single-source, single-source co-licensed, and multi-source originator
products as brand drugs, and all others as generics. We identified the top 25 brand, top 25 generic, and top 100
generic drugs by the total number of paid prescriptions for each drug. We used the MDDB to identify the drug
name, American Hospital Formulary System (AHFS) therapeutic class, and AHFS therapeutic subclass for each
product. We then calculated the weighted average AWP, WAC, NADAC, and actual amount paid by state
Medicaid agencies, for the top 25 brand, top 25 generic, top 100 generic, therapeutic class, and therapeutic
subclass. We weighted each drug at the NDC level using the total number of prescriptions dispensed to
Medicaid beneficiaries.
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AMP-Based FULs

EAC/AAC Benchmarks

Topic

Author &
Publication
Year
OIG, 2005

The OIG found that AMP was 23 percent lower than AWP for single-source brands, 28 percent
lower for multiple-source brands, and 70 percent lower than AWP for generics (all differences
measured at the midpoint of the distribution in the sample). AMP was 4 percent lower than
WAC for single-source brands, 8 percent lower for multiple-source brands, and 25 percent
lower for generics. There was much more variation in the percentage differences between
AMP and published prices for generics than for brands.53

OIG,
2011

The OIG compared AMPs, AWPs, and WACs to November 2010 invoice prices from a sample
of pharmacies (as a proxy for acquisition costs). Invoice prices were generally about 15-20
percent lower than AWPs for single-source brands, with some larger differences among
multiple-source brands. Invoice prices for generics without FULs ranged from 5 percent to 95
percent less than AWP, with no consistent relationship. WAC and AMP values were about the
same as invoice prices for single-source brands but, as with AWP, the relationships were
much more variable for multiple-source brands and generics without FULs. AMP was the least
consistent benchmark.54

GAO,
2013

Using 2013 data, the GAO compared draft AMP-based FULs to NADACs, and found that in the
aggregate, the two were within a few percentage points. However, breaking the drugs out
into brand and generic, but keeping the comparison in the aggregate, the GAO found that
the generic draft AMP-based FULs were 19 percent higher than generic NADACs, and the
brand draft AMP-based FULs were 26 percent lower than brand NADACs.55

GAO,
2010

Using 2008 data, the GAO compared estimated AMP-based FULs with average retail
pharmacy acquisition costs computed by IMS Health and found that acquisition costs were
higher than AMP-based FULs for most of the studied drugs, and in the aggregate.56 After
revising their estimates in 2010 to reflect changes to AMP-based FUL calculations included in
the Affordable Care Act, the GAO concluded that AMP-based FULs were at least 35 percent
higher than pharmacies’ acquisition costs, in aggregate.57

OIG,
2012

The OIG compared pharmacy invoice data with FULs using the current method based on
published prices and the revised, AMP-based FULs yet to be implemented by CMS. Invoice
prices were four times lower than FULs based on published prices, and about 43 percent
lower than AMP-based FULs, in aggregate.58

A Fein,
2011

Analysis of the draft AMP-based FULs published by CMS in 2011 indicated that AMP-based
payments for generic drugs could be about 40 percent lower than current federal and state
payment levels, but because generics are comparatively inexpensive, the impact is smaller
when including dispensing fees.59 Another analysis by the same author indicated that AMP
values vary considerably from month-to-month.60
These findings are consistent with another analysis by the OIG, which found that 24 percent
of AMP values fluctuated by more than 10 percent from quarter to quarter; AMPs for highexpenditure drugs and single-source drugs had the most frequent changes.61

OIG,
2007

State MAC
Pricing

Findings

OIG,
2009 &
2010
OIG,
2013

These OIG analyses raised concerns about the accuracy and consistency of AMP values. 62,63
The OIG compared FULs to State Maximum Allowable Costs (state MACs) in a 2013 report,
and found that FUL amounts using current methods based on published prices were almost
twice the amount of state MAC prices, in aggregate. AMP-based FUL amounts were 22
percent lower than state MAC prices, in the aggregate. In addition, the OIG found that state
MAC programs include 50-60 percent more drugs than FULs. Of 41 states that identified a
pricing benchmark for their state MAC programs, 29 used pharmacy acquisition costs as part
of the benchmark to set state MAC prices.64
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